However, in contrast to these findings, Losartan, an angiotensin inhibitor with anti-fibrotic effects, previously shown to inhibit collagen I production by CAFs and reduce stromal collagen in a pancreatic cancer mouse model [90] was able to reduce both stromal collagen and hyaluronan, potentially via inhibition of TGFβ1, and allow enhanced drug delivery [91]. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.